Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Center for Biologics Evaluation and Research CBER Vision:2004 - a strategic plan

This article was originally published in Clinica

Executive Summary

The FDA's Center for Biologics Evaluation & Research will unveil "CBER Vision:2004", its strategic plan for the next decade, at a vaccines advisory committee meeting this week. CBER director Kathy Zoon is excited about the plan for the agency which regulates a good amount of blood-related technology. Manufacturers of blood washers, warmers and freezers and other equipment used in blood banks; in vitro diagnostics manufacturers whose products are used in screening for manufacturing or transfusion; sources of HIV tests and their associated hardware will all be affected.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT093776

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel